AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03203226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FELDENKRAIS METHOD (FM)
Description: They EG will receive the intervention of FM consisting of 30 lessons (1h-lesson per week; 30 weeks) verbal instructions provided by the therapist to participants. These instructions provide different options on how to perform a specific task with the purpose of leaving the decision on how to do the movement up to the performer, who has to focus on thinking, feeling, sensing and doing the movement as easily as possible.The lessons can be conducted sitting, standing or moving within a room.
Study NCT01167049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPECITABINE
Description: Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);
Study NCT02897726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1402
Description: Oral
Study NCT02897726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1402R
Description: Oral
Study NCT02594189 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Live recombinantly derived A/Bethesda/MM1/H3N2 virus
Description: The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
Study NCT02004821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.
Study NCT02956369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control granulates (maize starch and long-chain fatty acids) with powder
Study NCT02956369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SATIOSTAT
Description: SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder
Study NCT03105986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575
Description: Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.
Study NCT03105986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).
Study NCT01489124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: 0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
Study NCT01489124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: 0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Study NCT01489124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: 1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Study NCT02101372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: case management
Study NCT02101372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation group treatment
Description: Psychoeducation therapy problem solving focus
Study NCT03338803 — intervention group
Intervention type: DRUG
Intervention: Linagliptin
Description: drug
Study NCT00828724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10mg
Study NCT04458025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation program
Description: Standard rehabilitation will start 4 weeks after surgery according to the standard of cre
Study NCT04458025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early rehabilitation program
Description: Early rehabilitation program will start 2 weeks
Study NCT01670734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous
Study NCT04045132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media-Based Parenting Program
Description: Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, in order to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. For each topic, we organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily, provides feedback to participants, and removes inappropriate postings if they occur. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed (engagement) and counts of sessions viewed and comments posted (dosage). Women in the intervention group will also be enrolled in the online depression treatment program, MoodGym.
Study NCT04045132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MoodGym
Description: Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. We will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
Study NCT04045132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoodGym
Description: Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. We will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
Study NCT03219606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organized education course of Modified Rodnan Skin Scoring
Description: 1. Lecture: An expert rheumatologist (master instructor) give a lecture to explain the technique of Modified Rodnan Skin Scoring (MRSS).~2. Demonstration: Master instructor demonstrate the patient assessment without revealing his score.~3. Practical training: Participants assess the MRSS of 8 patients with systemic sclerosis. Two other expert rheumatologists assist the course.
Study NCT04108494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of omentectomy
Description: Partial omentectomy with preservation of the greater omentum at >3 cm from the gastroepiploic arcade.Control group with total omentectomy.
Study NCT01152359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice
Description: Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
Study NCT01152359 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
Study NCT01230424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: 40 mg into the study knee joint every 12 weeks for a total of 8 injections.
Study NCT01230424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection as Placebo
Description: Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
Study NCT04476407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benapenem
Description: single-dose Benapenem 1.0mg(iv), 60min infusion
Study NCT03887507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vojta Therapy
Description: Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling reflex, and 1st phase and 2nd phase Rolling reflex.
Study NCT03887507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Program
Description: The program consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept.
Study NCT00546117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lansoprazole
Description: Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing >30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.
Study NCT00546117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Solutab in 15 and 30 mg dosages.
Study NCT02012738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FORNET
Description: 8 individual sessions:~* 1 lifeline~* 6 exposure sessions~* 1 outlook
Study NCT02012738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: 7 individual sessions, according to the Integrated cognitive behavior change program manual, Bush et al., 1997, National Institute of Corrections, US Dept. of Justice.
Study NCT02012738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List Control Group (camp)
Description: Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
Study NCT02012738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List Control Group (no camp)
Description: Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
Study NCT02339129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SST-0225
Description: SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
Study NCT02339129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
Study NCT02017912 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurown MSC-NTF cells
Description: Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
Study NCT02017912 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipient administration by combined intramuscular and intrathecal administration
Study NCT01770366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weight and Exercise Lifestyle Support (WELS)
Description: Intervention patients will receive a suite of devices manufactured by the FitLinxx company, including their Pebble activity monitor, ActiScale weight scale, and access to their ActiHealth.com patient portal website. Intervention participations will be able to use the features of this website, including widgets displaying their device data as well as challenge invitations to interact with other participants, as desired.
Study NCT01770366 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study NCT00742508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK&F-105517-D 10 mg capsule
Description: 1 capsule once a day
Study NCT00742508 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carvedilol-immediate release (IR) 2.5 mg tablet
Description: 1 or 2 tablet(s) twice a day
Study NCT00742508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK&F-105517-D 20 mg capsule
Description: 1 capsule once a day
Study NCT00742508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK&F-105517-D 40 mg capsule
Description: 1 or 2 capsule(s) once a day
Study NCT00742508 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carvedilol-IR 10 mg tablet
Description: 1 tablet twice a day
Study NCT04606823 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally invasive surgery
Description: The subjects will be implanted with a bone anchored hearing system using a minimally invasive surgery.
Study NCT04606823 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glasgow Benefit Inventory (GBI)
Description: A quality of life-questionnaire is to be completed by the subjects at one occasion.
Study NCT04606823 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Additional follow-up visits after surgery
Description: There are 1-3 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
Study NCT00352053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: Tenofovir DF 300-mg tablet, administered orally, daily + OBR
Study NCT00352053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tenofovir DF Placebo administered orally, daily + OBR
Study NCT00735293 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VASER
Description: A small incision will be made in the underarm. A VASER probe will be inserted under the skin to break apart fat and sweat glands under the skin. A small hollow tube will be used to draw out the broken-down skin and the incision will be closed with a stitch.
Study NCT03900143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tightra vaginal device
Description: Vaginal device for improvement of vaginal symptoms, reduce vaginal laxity, improve sexual functioning, and treat stress urinary incontinence.
Study NCT01001780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin; Cyclophosphamide; Rituximab
Description: Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
Study NCT02583568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-800CW
Description: three days prior to surgery bevacizumab-800CW will be administered
Study NCT03601104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity eccentric training
Description: High intensity eccentric training group with 80% of isometric peak torque.
Study NCT03601104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity eccentric training with BFR
Description: Eccentric high intensity training group with 80% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
Study NCT03601104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity eccentric training with BFR
Description: Low intensity eccentric training group with 40% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
Study NCT03601104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity eccentric training
Description: Low intensity eccentric training group with 40% of isometric peak torque
Study NCT01003184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 2mg, once a week
Study NCT01003184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day
Study NCT04657549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Tonsillectomy is done by monopolar electrocautery, bipolar scissors or cold instruments. First the mucosa of the anterior palatinal arch is incised and tonsillar capsule identified, then tonsillar tissue is removed along the capsule. Any bleeding is coagulated either with monopolar or bipolar electrocautery.
Study NCT04657549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillotomy
Description: Tonsillotomy is done using monopolar electrosurgery, bipolar scissors or coblator device. Most of the tonsillar tissue is removed, exceeding the removal behind the line between anterior and posterior palatinal arch so that only thin layer of tonsil tissue is left over the tonsillar capsule.
Study NCT00557622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)
Study NCT00557622 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00227760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study NCT00227760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Correlative studies
Study NCT00227760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00227760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01578096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stress management
Description: The study is a randomized, controlled,single-site, parallel group clinical trial comparing the effectiveness of CHW led diabetes education with CHW led diabetes education plus CHW led stress management in Latinos with Type 2 Diabetes.
Study NCT04005937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: H-reflex
Description: Electrical stimulation of Group Ia afferent of muscle spindle
Study NCT00000143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ganciclovir implant and oral ganciclovir
Description: oral ganciclovir, 1 gm three times daily
Study NCT00000143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir intravenous
Description: intravenous, 5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week
Study NCT03013686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interval appendectomy
Description: Laparoscopic appendectomy
Study NCT03013686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up with MRI
Description: Abdominal MRI
Study NCT02803320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 Y65 110 (BAY 987516)
Description: Subjects applied the assigned products to all sun-exposed areas of their face and body liberally and evenly, in accordance with instructions. Sun exposure was divided into two periods. Each period consisted of direct sun exposure (out of water; Cycle A) and water exposure (Cycle B). Cycles A and B were repeated two times before study closeout.
Study NCT00874289 — intervention group
Intervention type: OTHER
Intervention: NGAL kit
Description: Kit to test NGAL levels in heart failure patients
Study NCT04503538 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine visit
Description: Participants will be provided with a Wifi-and cellular enabled electronic tablet. Additionally, participants will receive a kit that contains a thermometer, a blood pressure monitoring cuff, and a pulse oximeter (to measure oxygen saturation level). Participants will attend an educational session to learn how the telemedicine visit works. Caregivers should attend with participants and will be trained to take temperatures, blood pressures, and oxygen saturation levels. Participants will also be asked to complete a test telehealth visit.
Study NCT03802162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-355A (D797/Memantine HCl 20mg)
Description: once a day
Study NCT03802162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-355B (D797/Memantine HCl 20mg)
Description: once a day
Study NCT03802162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D797
Description: once a day
Study NCT03802162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D324 (Memantine HCl 10mg)
Description: twice a day